筛查超声发现的乳晕后肿块与导管内异常:能否避免活检?
本研究回顾性分析2009年10月1日至2015年5月30日期间筛查全乳腺超声发现的87个BI-RADS 3或4类乳晕后肿块或导管内异常,其中BI-RADS 3类47个、4类40个,恶性肿瘤率分别为2.1%和0%,总体为1.1%。作者认为对无症状、钼靶阴性的此类病变,仔细影像随访替代活检可能是合适的。
要点
- 筛查超声发现的BI-RADS 3类乳晕后病变恶性率2.1%,4类为0%。
- BI-RADS 3类病变中仅1例5 mm 2级导管原位癌在随访间隔变化后活检确诊。
- 无症状、钼靶阴性者,作者认为仔细影像随访替代活检可能是合适的。
核心结论
- 筛查全乳腺超声发现的BI-RADS 3和4类乳晕后肿块及导管内异常的恶性率低(<2%),总体为1.1%。
研究设计与样本
- HIPAA合规的回顾性研究,检索2009年10月1日至2015年5月30日放射学电子病历,纳入无症状女性、钼靶正常且致密乳腺、有影像或活检随访的乳晕后肿块或导管内异常,共87个BI-RADS 3或4类病灶。
关键影像表现/征象
- 病灶平均大小9.5 mm(范围4-28 mm)。
- 47/87个病灶归为BI-RADS 3类,40/87个归为BI-RADS 4类。
- 47个BI-RADS 3类病灶中36个随访稳定,6个应患者要求活检为良性,5个因随访影像可疑间隔变化而活检,其中4个良性、1个为5 mm 2级导管原位癌。
- 40个BI-RADS 4类病灶中3个未活检且随访稳定,37个活检均为良性。
诊断标准与关键数值
- BI-RADS 3类乳晕后病变恶性率2.1%[CI(0.4-11.1)]。
- BI-RADS 4类乳晕后病变恶性率0%[CI(0.0-8.8)]。
- 总体合并恶性率1/87[1.1%,CI(0.2-6.2)]。
临床应用与阅片要点
- 作者认为,对无症状、钼靶阴性的BI-RADS 3和4类乳晕后肿块及导管内异常,仔细影像随访替代活检可能是合适的。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
UNLABELLED: To investigate the malignancy rate of retroareolar masses and intraductal abnormalities discovered in asymptomatic females during screening whole breast ultrasound (US-S) and determine if biopsy can be avoided.
METHODS:: This is a HIPAA compliant retrospective study. Our radiology electronic medical records were searched for the phrases "retroareolar mass" or "intraductal mass" combined with "screening whole breast ultrasound" performed between 10/1/2009 and 5/30/2015. Inclusion criteria included retroareolar masses in asymptomatic females with normal mammography, mammographically dense breast tissue and imaging or biopsy follow-up.
RESULTS:: 1136 charts were reviewed. 87 BI-RADS 3 and 4 retroareolar findings were included in final analysis. The average lesion size was 9.5 mm (range 4-28 mm). 47/87 lesions were classified as BI-RADS 3 and 40/87 BI-RADS 4. Of the 47 BI-RADS 3 lesions, 36 were stable on follow-up; 6 benign lesions were biopsied at patients' request; and 5 biopsied due to suspicious interval change on follow-up imaging, including 4 benign lesions and a 5 mm Grade 2 ductal carcinoma in situ . 3/40 BI-RADS 4 lesions were not biopsied and stable at follow-up; 37/40 lesions underwent benign biopsy. The malignancy rate of BI-RADS 3 and 4 lesions was 2.1% [CI (0.4-11.1)] and 0% [CI (0.0-8.8)], respectively. The overall combined malignancy rate was 1/87 [1.1%, CI (0.2-6.2)].
CONCLUSION:: The malignancy rate for BI-RADS 3 and 4 retroareolar masses and intraductal abnormalities detected on US-S is low (<2%).
ADVANCES IN KNOWLEDGE:: Careful imaging surveillance in lieu of biopsy of these lesions may be appropriate in asymptomatic females with negative mammography.
引用
- Guo Y, Raghu M, Durand M, et al. Retroareolar masses and intraductal abnormalities detected on screening ultrasound: can biopsy be avoided? Br J Radiol. 2018. PMID: 29338316. doi:10.1259/bjr.20170816
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。